Trump Administration to Examine Safety of Psychedelic Drug for PTSD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PBM?
Source: Yahoo Finance
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Psyence BioMed Welcomes U.S. Executive Order on Ibogaine Research
- Executive Order Impact: Psyence BioMed acknowledges the U.S. administration's preparation of an executive order to evaluate ibogaine's safety and therapeutic potential, reflecting a growing emphasis on rigorous research into novel therapies, which may advance the company's clinical research in PTSD and addiction.
- CEO Statement: CEO Jody Aufrichtig expressed support for structured, evidence-based research to clarify ibogaine's safety and efficacy, which will enhance patient safety and long-term access, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- GMP Manufacturing Advantage: Through strategic investment in PsyLabs, Psyence BioMed has established a leading position in GMP-compliant manufacturing of ibogaine, supporting global clinical research and future therapeutic development while ensuring product quality and traceability.
- Ethical Sourcing Strategy: The company is committed to developing a responsible and ethical ibogaine supply chain that ensures sustainability and respects traditional practices, positioning Psyence BioMed's integrated platform to support the next phase of research and potential regulatory evolution as global interest in ibogaine accelerates.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Trump to Sign Executive Order on Psychedelic Research
- Stock Surge: Psyence Biomedical Ltd. (PBM) shares closed over 100% higher on Thursday and continued to rally by 42% on Friday, indicating the company is on track for its best trading week in over two years, reflecting strong market interest in psychedelic research.
- Executive Order Impact: The Trump administration is expected to sign an executive order this week aimed at opening federal funding for research on PTSD and traumatic brain injuries, although ibogaine will remain classified as a Schedule I drug, indicating a cautious governmental approach to psychedelic research.
- Strategic Investment: Psyence highlighted its strategic investment in Psylabs, a biopharmaceutical company in Southern Africa specializing in the cultivation and extraction of nature-derived psychedelic active pharmaceutical ingredients, showcasing the company's long-term commitment to the psychedelic sector.
- Market Sentiment: Retail sentiment around PBM stock has remained in the 'extremely bullish' territory over the past 24 hours, with message volume jumping from 'high' to 'extremely high', indicating strong investor interest in the upcoming research opportunities.
See More
Psyence Supports U.S. Regulated Research on Ibogaine
- Regulatory Research Support: Psyence Biomedical Ltd. expresses support for emerging U.S. regulatory efforts aimed at advancing research into Ibogaine, a naturally occurring psychedelic compound being studied for PTSD and addiction treatment.
- Drug Regulation Dynamics: Although Ibogaine remains a Schedule I substance in the U.S., with patients often seeking unregulated access abroad, the anticipated federal action indicates a growing recognition of the need for controlled evidence-based research, particularly for treatment-resistant conditions.
- Safety and Accessibility: CEO Jody Aufrichtig emphasizes that as global interest in Ibogaine accelerates, structured research and regulated development pathways are essential for improving patient safety and long-term access to these therapies.
- Business Development and Market Performance: PsyLabs, the company's Active Pharmaceutical Ingredient development arm, is federally licensed to cultivate, extract, and export psychedelic compounds, and the company recently executed a 16-for-100 reverse stock split, with current trading at $8.27, reflecting a 40.72% increase.
See More
Israel-Lebanon Ceasefire Boosts Market Sentiment
- Middle East De-escalation: The 10-day ceasefire between Israel and Lebanon has taken effect, leading markets to price in easing tensions, with crude oil prices falling below $100 per barrel and equities rising, indicating investor optimism about future stability.
- Futures Rise: As of 4:00 a.m. ET on Friday, Dow futures rose by 0.3%, S&P 500 futures gained 0.1%, Nasdaq futures remained flat, and Russell 2000 futures increased by 0.2%, reflecting a positive sentiment among investors regarding a potential resolution to the Middle East crisis.
- Netflix Shares Decline: Netflix shares fell nearly 10% in early pre-market trading following a disappointing guidance report, and the news of co-founder Reed Hastings exiting the board in June, although CEO Ted Sarandos noted the company's strong cash position.
- Defense Stocks Favorable: With geopolitical tensions easing, defense-linked companies have gained favor among investors, highlighting ongoing market interest in security and defense sectors amid shifting global dynamics.
See More
Psyence BioMed Welcomes U.S. Executive Order on Ibogaine Research
- Executive Order Impact: Psyence BioMed acknowledges the U.S. administration's preparation of an executive order to evaluate ibogaine's safety and therapeutic potential, reflecting a growing emphasis on rigorous research into novel therapies, which may advance the company's clinical research in PTSD and addiction.
- CEO Statement: CEO Jody Aufrichtig expressed support for structured, evidence-based research to clarify ibogaine's safety and efficacy, which will enhance patient safety and long-term access, thereby strengthening the company's competitive position in the biopharmaceutical sector.
- GMP Manufacturing Advantage: Through strategic investment in PsyLabs, Psyence BioMed has established a leading position in GMP-compliant manufacturing of ibogaine, supporting global clinical research and future therapeutic development while ensuring product quality and traceability.
- Ethical Sourcing Strategy: The company is committed to developing a responsible and ethical ibogaine supply chain that ensures sustainability and respects traditional practices, positioning Psyence BioMed's integrated platform to support the next phase of research and potential regulatory evolution as global interest in ibogaine accelerates.
See More
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
- Psychedelic Research Advancement: The Trump administration is drafting an executive order indicating a willingness to further investigate the safety and efficacy of ibogaine, a psychedelic used for treating PTSD, which is expected to accelerate clinical research in this area.
- Positive Market Reaction: Following the announcement, stocks of companies like Clearmind Medicine (CMND), Atai Beckley (ATAI), and Cybin (HELP) rose, reflecting market optimism regarding the potential applications of psychedelics in mental health treatment.
- Strait of Hormuz Passage Statement: Iran's Foreign Minister declared that commercial vessels can fully pass through the Strait of Hormuz during the ceasefire in Lebanon, while Trump confirmed normal passage but maintained a naval blockade against Iran, highlighting the complexities of geopolitical tensions in the region.
- AI Model Utilization: The U.S. government is preparing to make Anthropic PBC's AI model Mythos available to major federal agencies despite cybersecurity risks, indicating a balancing act between promoting technological innovation and ensuring data security.
See More
Health Care Stocks Rise 1.4% on NYSE
- Strong Performance in Health Care: The NYSE Health Care Index rose 1.4% late Friday afternoon, indicating a rebound in investor confidence towards the healthcare sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in healthcare stocks suggests that investors may be reassessing the growth potential of the healthcare industry while seeking safe-haven assets amid increasing economic uncertainty.
- Increased Investor Attention: The uptick in healthcare stocks could attract more investor interest, particularly as the healthcare sector is viewed as a relatively stable investment choice in the current economic climate, potentially leading to increased capital inflows.
- Optimistic Industry Outlook: The upward trend in the healthcare sector may reflect market optimism regarding future medical innovations and policy support, further driving stock price increases for related companies.
See More
Trump to Sign Executive Order on Psychedelic Research
- Stock Surge: Psyence Biomedical Ltd. (PBM) shares closed over 100% higher on Thursday and continued to rally by 42% on Friday, indicating the company is on track for its best trading week in over two years, reflecting strong market interest in psychedelic research.
- Executive Order Impact: The Trump administration is expected to sign an executive order this week aimed at opening federal funding for research on PTSD and traumatic brain injuries, although ibogaine will remain classified as a Schedule I drug, indicating a cautious governmental approach to psychedelic research.
- Strategic Investment: Psyence highlighted its strategic investment in Psylabs, a biopharmaceutical company in Southern Africa specializing in the cultivation and extraction of nature-derived psychedelic active pharmaceutical ingredients, showcasing the company's long-term commitment to the psychedelic sector.
- Market Sentiment: Retail sentiment around PBM stock has remained in the 'extremely bullish' territory over the past 24 hours, with message volume jumping from 'high' to 'extremely high', indicating strong investor interest in the upcoming research opportunities.
See More
Psyence Supports U.S. Regulated Research on Ibogaine
- Regulatory Research Support: Psyence Biomedical Ltd. expresses support for emerging U.S. regulatory efforts aimed at advancing research into Ibogaine, a naturally occurring psychedelic compound being studied for PTSD and addiction treatment.
- Drug Regulation Dynamics: Although Ibogaine remains a Schedule I substance in the U.S., with patients often seeking unregulated access abroad, the anticipated federal action indicates a growing recognition of the need for controlled evidence-based research, particularly for treatment-resistant conditions.
- Safety and Accessibility: CEO Jody Aufrichtig emphasizes that as global interest in Ibogaine accelerates, structured research and regulated development pathways are essential for improving patient safety and long-term access to these therapies.
- Business Development and Market Performance: PsyLabs, the company's Active Pharmaceutical Ingredient development arm, is federally licensed to cultivate, extract, and export psychedelic compounds, and the company recently executed a 16-for-100 reverse stock split, with current trading at $8.27, reflecting a 40.72% increase.
See More
Israel-Lebanon Ceasefire Boosts Market Sentiment
- Middle East De-escalation: The 10-day ceasefire between Israel and Lebanon has taken effect, leading markets to price in easing tensions, with crude oil prices falling below $100 per barrel and equities rising, indicating investor optimism about future stability.
- Futures Rise: As of 4:00 a.m. ET on Friday, Dow futures rose by 0.3%, S&P 500 futures gained 0.1%, Nasdaq futures remained flat, and Russell 2000 futures increased by 0.2%, reflecting a positive sentiment among investors regarding a potential resolution to the Middle East crisis.
- Netflix Shares Decline: Netflix shares fell nearly 10% in early pre-market trading following a disappointing guidance report, and the news of co-founder Reed Hastings exiting the board in June, although CEO Ted Sarandos noted the company's strong cash position.
- Defense Stocks Favorable: With geopolitical tensions easing, defense-linked companies have gained favor among investors, highlighting ongoing market interest in security and defense sectors amid shifting global dynamics.
See More
